Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use OMTRYG™ safely and effectively. See full prescribing information for OMTRYG. OMTRYG (omega-3-acid ethyl esters) capsules, USP, for oral useInitial U.S. Approval: 2004
Medication labelWhy this: Advisory · dailymed-prescription
OMTRYG™ (omega-3-acid ethyl esters) capsules, USP, is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Usage Considerations: Patients should be placed on an appropriate lipid-lowering diet before receiving OMTRYG and should continue this diet during treatment with OMTRYG. Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting OMTRYG therapy. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems, such as diabetes mellitus and hypothyroidism, that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. Limitations of Use: The effect of OMTRYG on the risk for pancreatitis has not been determined. The effect of OMTRYG on cardiovascular mortality and morbidity has not been determined.
- generic_name
- omega-3-acid ethyl esters
- product_names
- omega-3-acid ethyl esters
- ndc
- 61112-001, 61112-001-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en